About US

Leading the Future of Medical Aesthetics through Innovative Silk Technology,
Technology Dersmithson.

Dersmithson is an R&D specialized enterprise dedicated to developing high-end composite fillers. We combine "Silk Fibroin"—the most noble natural protein discovered by humanity—with next-generation polymer materials, utilizing our proprietary extraction technology. Our journey began on the global stage, connecting Korea, China, and the United States under the name Maxgen. Over the years, our original technologies have been recognized by numerous global partners, leading to successful patent registrations and technology transfers. We have consistently spearheaded innovation in the field of biomaterials.

Today, we are embarking on a second leap forward as Dersmithson, headquartered in Poland, the heart of Europe. Dersmithson's composite fillers focus on more than just enhancing aesthetic appearance; we are committed to achieving the safest and most natural biocompatibility for the human body. By integrating the technological assets accumulated through Maxgen with Dersmithson's sophisticated research capabilities, we provide premium solutions that medical professionals and clients worldwide can trust.

We believe that the value of technology truly shines when it enriches human life. Through continuous R&D investment and rigorous quality control, we promise to set a new global standard in the medical aesthetic market.

Thank you.
CEO, Dersmithson

"The First and Only Silk Fibroin Technology"

The Limits of Others, The Genesis of DERSMITHSON

The Challenge: A Decade of Research, The Unbroken Barrier

Silk fibroin has long been revered as the "dream material" in medical aesthetics for its unparalleled biocompatibility. While global industry leaders have spent the last decade striving to commercialize this innovative substance, most remain confined to the research stage, unable to bridge the gap between theory and reality due to three critical technical challenges:

Structural Denaturation: The inherent collapse of protein structures during the purification process.
Stability Limitations: The lack of advanced technology required to maintain formulation integrity without relying on synthetic chemical cross-linkers.
Immunogenic Risks: The persistent risk of adverse reactions stemming from the incomplete elimination of impurities.

The Breakthrough: ND-SF™ Technology

DERSMITHSON has finally overcome these long-standing industry barriers through our proprietary "ND-SF (Non-Denatured Silk Fibroin)" technology. By preserving the natural integrity of the protein without chemical modification, we have unlocked the true potential of silk fibroin for the future of medical aesthetics.

"Fibroin Stabilization Technology," surmounting the limitations of the existing market and realizing the commercialization of silk that the world has long awaited.

Category	Global Competitors (R&D Phase)	DERSMITHSON (Successful Commercialization)
Purification Technology	Protein denaturation occurs during processing	High-purity extraction; preservation of native protein structure
Cross-linking Method	Reliance on chemical cross-linkers (Residual toxicity)	Cross-linker-free (Non-cross-linked) stabilization
Biocompatibility	Risk of immune response due to incomplete purification	Ultra-purification process applied for maximum safety
Current Status	Delayed commercialization	Successful product commercialization and mass production

Our Mission

Driven by advanced regenerative medicine and tissue engineering, DERSMITHSON sp. z o.o. leads the way in developing high-performance aesthetics and medical fillers.

Our mission is to redefine aging and elevate the quality of life through scientific innovation.

= Anti-adhesion anti-cancer
= Biodegradable polyners for DDS systems.
= PLG.PLLA.PDO.PEG.Dextran..Microssphere

Drug loading of microsphere

Sustained release of drug –loaded PLGA microspheres

Controlled drug delivery system

It can release drugs within a consistent concentration range and maintain a steady level of the drug in the bloodstream.

It can reduce the risk of shock caused by a high concentration of the drug after injection.

It can reduce the frequency of drug administration via injection.

A technology designed to maintain drug levels within the therapeutic window, between the maximum safe concentration and the minimum effective concentration
(a key requirement for regulatory clearance)

Fibroin: A complex product of fibroin alpha and beta

Dual-Action Hydration: The Alpha-helix ensures deep moisture delivery, while the Beta-sheet creates a breathable film to lock in hydration and prevent water loss.

Regenerative Support: The hybrid structure acts as a bioactive scaffold that promotes fibroblast proliferation, boosting natural collagen synthesis and skin elasticity.

Skin Barrier Protection: The structural stability of the Beta-sheet shields the skin from environmental stressors, while the biocompatible Alpha-helix soothes irritation.

Superior Sensory Profile: Provides an immediate silky smooth finish and helps refine skin texture by filling in fine lines and irregularitie

Patent

10-1670249 Anticancer Drug Delivery and Manufacturing Method thereof

10-2024-0187809 Hydrogel composition comprising silk fibroin for tissue Regeneration And method of application thereof

10-2025-0160747 Biocompatible Tissue-Engineered Dermal Filler Comprising A Complex of PLA Microspheres and Alpha-Structured Fibroin For Enhanced Skin Regeneration and It's Manufacturing Method.

Dersmithson has researched and developed numerous cosmetic and medical filler etc products through innovative tissue engineering technologies over the past 20 years,
In addition, many patents and technologies were transferred to various companies.

<Patent> Porous Bio-degradable and artificial organs as hoe to reduce.

<Patent> Method for penile augmentation using autologous dermis cell culture. (US6,465,000 B1)

<Patent> Hydro gel enhanced anti-adhesion barrier.

<Patent> Injectable polymer biodegradable granules for tissue regeneration and how to produce method there of.

<Patent> Hydrogel product comprising polyion complex and method there of.

(Tractate of AJA)
Tissue engineering penoplasty with Biodegradable Scaffold Maxpol-T Co-grafted Autologous Fibroblasts
Running title: Tissue Engineering Penoplasty with Maxpol-T